What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort
- 22 May 2014
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 73 (9), 1695-1699
- https://doi.org/10.1136/annrheumdis-2014-205318
Abstract
Objective To determine whether serial ANA testing predicts biological disease modifying antirheumatic drugs (bDMARD)-associated ANA/dsDNA production in patients with rheumatoid arthritis (RA). Methods Serial autoantibody profiles, bDMARD treatment sequences and clinical data were collected from patients identified from our database that since 2005 received (i) a first bDMARD (tumour necrosis factor inhibitor (TNFi)) and (ii) tocilizumab and/or abatacept. Results Of over 1000 patients, 454 RA patients received a first TNFi. Infliximab group demonstrated higher ANA seroconversion rates (31.2%) compared with etanercept (11.8%) and adalimumab (16.1%) (pConclusions This study demonstrates no utility of serial ANA/dsDNA testing that could be used to predict onset of seroconversion and therefore the development of lupus/vasculitis. An association however between seroconversion and the development of a secondary non-response to bDMARD therapy is suggested.This publication has 24 references indexed in Scilit:
- Biologics-induced autoimmune diseasesCurrent Opinion in Rheumatology, 2013
- Autoimmune diseases induced by biological agents: A double-edged sword?Autoimmunity Reviews, 2010
- Vasculitides induced by TNFα antagonists: a study in 39 patients in FranceJoint Bone Spine, 2006
- Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national surveyArthritis Research & Therapy, 2005
- Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomideArthritis & Rheumatism, 2004
- Drug-induced systemic lupus erythematosus associated with etanercept therapyThe Lancet, 2002
- Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trialsArthritis & Rheumatism, 2000
- Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis & Rheumatism, 1998
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993